Comparative Pharmacology
Head-to-head clinical analysis: PENICILLIN 2 versus STAPHCILLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENICILLIN 2 versus STAPHCILLIN.
PENICILLIN-2 vs STAPHCILLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
Semisynthetic penicillin; inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
250 mg orally every 6 hours or 500 mg orally every 8 hours for mild to moderate infections; intravenous dosing: 1-2 million units every 4-6 hours.
1-2 g IV every 4-6 hours.
None Documented
None Documented
30-60 minutes; prolonged in renal impairment (up to 10 hours in anuria)
0.5-1 hour in adults with normal renal function; prolonged to 2-4 hours in renal impairment. Infants: 1-2 hours.
Renal: 60-80% unchanged; biliary/fecal: minor (10-20%)
Primarily renal (70-90% as unchanged drug via glomerular filtration and tubular secretion); minor biliary excretion (<5%) and fecal elimination (<1%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic